Mark Field

It seems we can’t find what you’re looking for. Perhaps searching can help.

Search for:

Search

Recent Posts

Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD
Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2
Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities